Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

KRRO

Korro Bio Inc

Feb 09 • 04:00PM ET

12.72

+0.15 1.19 %

Healthcare • Biotechnology • USA • NASD

Peers: BEAM EDIT NTLA CRSP RGNX FDMT VYGR ARVN SGMO CRBU

| Held by: IWM VTI LFSC IWN VXF VTWO IWC ITOT VHT IWV

Index	RUT	P/E	-	EPS (ttm)	-9.42	Insider Own	45.78%	Shs Outstand	9.40M	Perf Week	-2.53%
Market Cap	119.79M	Forward P/E	-	EPS next Y	-8.10	Insider Trans	0.00%	Shs Float	5.11M	Perf Month	39.02%
Enterprise Value	70.98M	PEG	-	EPS next Q	-2.07	Inst Own	71.36%	Short Float	21.35%	Perf Quarter	-60.95%
Income	-88.42M	P/S	16.25	EPS this Y	3.63%	Inst Trans	18.36%	Short Ratio	2.00	Perf Half Y	-20.50%
Sales	7.37M	P/B	1.21	EPS next Y	10.33%	ROA	-43.65%	Short Interest	1.09M	Perf YTD	58.80%
Book/sh	10.54	P/C	1.28	EPS next 5Y	5.84%	ROE	-63.46%	52W High	55.89 -77.24%	Perf Year	-64.88%
Cash/sh	9.93	P/FCF	-	EPS past 3/5Y	57.64% 21.83%	ROIC	-62.91%	52W Low	5.20 144.41%	Perf 3Y	-93.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-45.55% -39.89%	Gross Margin	33.82%	Volatility	8.84% 9.20%	Perf 5Y	-99.46%
Dividend TTM	-	EV/Sales	9.63	EPS Y/Y TTM	21.61%	Oper. Margin	-1282.04%	ATR (14)	1.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.71	Sales Y/Y TTM	-	Profit Margin	-1199.53%	RSI (14)	63.29	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.71	EPS Q/Q	14.80%	SMA20	16.46%	Beta	2.97	Target Price	22.38
Payout	-	Debt/Eq	0.45	Sales Q/Q	-	SMA50	42.21%	Rel Volume	0.16	Prev Close	12.57
Employees	104	LT Debt/Eq	0.42	Earnings	Nov 12 AMC	SMA200	-33.89%	Avg Volume	546.14K	Price	12.72
IPO	Oct 03, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.98% 67.56%	Trades		Volume	85,467	Change	1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight	$30
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$15
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform	$22
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$21
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$8
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral	$11
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100

Show Previous Ratings

Feb-02-26 09:53AM	H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO) (Insider Monkey)
Jan-30-26 07:35AM	Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? (Zacks)
03:08AM	Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE (MarketBeat)
Jan-29-26 09:35AM	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls (The Fly) +13.86%
Jan-20-26 08:00AM	Korro to Host Virtual Analyst Day on January 27, 2026 (GlobeNewswire)
08:00AM	Loading…
Jan-08-26 08:00AM	Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.77%
Nov-13-25 09:37AM	Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing (Investor's Business Daily) -79.31%
09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
Nov-12-25 05:59PM	This biotech is halting its work with Novo Nordisk and laying off more people (MarketWatch)
05:40PM	Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs (GlobeNewswire)
Sep-02-25 04:30PM	Korro to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire) +17.25%
Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
10:31AM	Loading…
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
04:05PM	Loading…
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Open in Screener

DYN

Dyne Therapeutics Inc

Feb 09 • 04:00PM ET

16.99

+0.19 1.13 %

Healthcare • Biotechnology • USA • NASD

DYN Dyne Therapeutics Inc daily Stock Chart

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI XBI IWM VB VXF VBR IBB IWN VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.66	Insider Own	23.31%	Shs Outstand	142.61M	Perf Week	-9.43%
Market Cap	2.75B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-0.03%	Shs Float	124.10M	Perf Month	-6.96%
Enterprise Value	2.08B	PEG	-	EPS next Q	-0.76	Inst Own	84.36%	Short Float	15.22%	Perf Quarter	-6.67%
Income	-423.80M	P/S	-	EPS this Y	-3.91%	Inst Trans	32.82%	Short Ratio	7.54	Perf Half Y	52.24%
Sales	0.00M	P/B	3.50	EPS next Y	7.20%	ROA	-51.81%	Short Interest	18.89M	Perf YTD	-13.14%
Book/sh	4.85	P/C	3.47	EPS next 5Y	4.87%	ROE	-60.66%	52W High	25.00 -32.04%	Perf Year	1.37%
Cash/sh	4.89	P/FCF	-	EPS past 3/5Y	-4.75% -59.45%	ROIC	-52.50%	52W Low	6.36 167.14%	Perf 3Y	20.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.24% 5.78%	Perf 5Y	-16.47%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.75%	Oper. Margin	-	ATR (14)	1.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.47	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.44	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	13.47	EPS Q/Q	20.87%	SMA20	-3.20%	Beta	1.32	Target Price	39.12
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	-9.76%	Rel Volume	0.73	Prev Close	16.80
Employees	191	LT Debt/Eq	0.17	Earnings	Nov 05 AMC	SMA200	15.12%	Avg Volume	2.51M	Price	16.99
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.21% -	Trades		Volume	1,860,479	Change	1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15

Show Previous Ratings

Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
07:30AM	Loading…
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Loading…
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Loading…
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
06:30AM	Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts (GlobeNewswire)
Aug-29-24 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-24 10:52PM	DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
05:10PM	Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 08:50AM	Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why (Zacks)
Jul-18-24 12:00PM	What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-12-24 08:50AM	Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-24 07:30AM	Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (GlobeNewswire)
Jun-13-24 04:40PM	Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress (GlobeNewswire)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kerr Douglas	Officer	Dec 05 '25	Proposed Sale	20.72	880	18,231		Dec 05 04:56 PM
Cox John	Officer	Dec 05 '25	Proposed Sale	20.72	2,662	55,150		Dec 05 04:55 PM
Cox John	CEO & President	Dec 05 '25	Sale	20.72	2,662	55,157	196,877	Dec 05 04:11 PM
Kerr Douglas	Chief Medical Officer	Dec 05 '25	Sale	20.72	880	18,234	87,510	Dec 05 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Dec 05 '25	Sale	20.72	144	2,984	94,729	Dec 05 04:08 PM
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 13 '25	Sale	12.12	143	1,733	96,057	Mar 13 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '25	Sale	11.38	1,343	15,283	122,330	Mar 13 04:08 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '25	Sale	11.38	2,153	24,501	195,840	Mar 13 04:08 PM
Beskrovnaya Oxana	Officer	Mar 11 '25	Proposed Sale	11.38	2,153	24,493		Mar 11 04:09 PM
Scalzo Richard William	Officer	Mar 11 '25	Proposed Sale	11.38	1,343	15,278		Mar 11 04:08 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '25	Sale	11.83	1,343	15,888	94,157	Mar 07 04:08 PM
Cox John	CEO & President	Mar 05 '25	Sale	11.83	4,061	48,042	146,239	Mar 07 04:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 05 '25	Sale	11.83	917	10,848	123,673	Mar 07 04:06 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 05 '25	Sale	11.83	1,094	12,942	197,993	Mar 07 04:04 PM
Kerr Douglas	Officer	Mar 05 '25	Proposed Sale	11.89	1,343	15,968		Mar 05 04:10 PM
Cox John	Officer	Mar 05 '25	Proposed Sale	11.89	4,067	48,356		Mar 05 04:09 PM
Beskrovnaya Oxana	Officer	Mar 05 '25	Proposed Sale	11.89	1,094	13,007		Mar 05 04:08 PM
Scalzo Richard William	Officer	Mar 05 '25	Proposed Sale	11.89	915	10,879		Mar 05 04:07 PM
Beskrovnaya Oxana	Chief Scientific Officer	Feb 18 '25	Sale	13.95	2,598	36,242	199,087	Feb 25 05:09 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 18 '25	Sale	13.95	2,488	34,708	124,590	Feb 18 05:09 PM
Scalzo Richard William	Officer	Feb 18 '25	Proposed Sale	13.91	2,488	34,608		Feb 18 04:15 PM
Beskrovnaya Oxana	Officer	Feb 18 '25	Proposed Sale	13.91	2,598	36,138		Feb 18 04:14 PM

Open in Screener

DAWN

Day One Biopharmaceuticals Inc

Feb 09 • 04:00PM ET

11.72

+0.31 2.72 %

Healthcare • Biotechnology • USA • NASD

DAWN Day One Biopharmaceuticals Inc daily Stock Chart

Peers: VRTX NBIX BPMC SRPT EXEL FATE IGMS KURA BHVN PBYI

| Held by: XBI VTI IWM VB VXF IWN IBB VBR SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.49	Insider Own	28.27%	Shs Outstand	102.68M	Perf Week	1.91%
Market Cap	1.24B	Forward P/E	-	EPS next Y	-0.57	Insider Trans	-0.19%	Shs Float	75.82M	Perf Month	26.70%
Enterprise Value	790.17M	PEG	-	EPS next Q	-0.17	Inst Own	72.12%	Short Float	15.00%	Perf Quarter	30.37%
Income	-151.76M	P/S	9.27	EPS this Y	3.39%	Inst Trans	1.23%	Short Ratio	4.12	Perf Half Y	92.13%
Sales	133.67M	P/B	2.67	EPS next Y	41.82%	ROA	-27.23%	Short Interest	11.38M	Perf YTD	25.75%
Book/sh	4.39	P/C	2.74	EPS next 5Y	-	ROE	-30.16%	52W High	13.20 -11.21%	Perf Year	-6.31%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	28.09% -38.09%	ROIC	-33.46%	52W Low	5.64 107.99%	Perf 3Y	-46.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.44%	Volatility	7.05% 8.56%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.91	EPS Y/Y TTM	-46.75%	Oper. Margin	-123.90%	ATR (14)	0.85	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.55	Sales Y/Y TTM	31.11%	Profit Margin	-113.53%	RSI (14)	57.91	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.68	EPS Q/Q	-149.93%	SMA20	3.15%	Beta	-1.27	Target Price	22.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	-57.56%	SMA50	18.49%	Rel Volume	0.68	Prev Close	11.41
Employees	181	LT Debt/Eq	0.01	Earnings	Nov 04 AMC	SMA200	49.56%	Avg Volume	2.76M	Price	11.72
IPO	May 27, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.01% 5.21%	Trades		Volume	2,493,886	Change	2.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-26	Resumed	TD Cowen	Buy	$34
Aug-19-25	Initiated	Piper Sandler	Overweight	$25
Oct-09-24	Reiterated	Needham	Buy	$32 → $33
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy	$11 → $24
Apr-24-24	Reiterated	Needham	Buy	$30 → $33
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform	$34 → $9
Feb-08-23	Initiated	CapitalOne	Overweight	$40
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy	$35
Dec-14-22	Initiated	Needham	Buy	$40
Dec-05-22	Initiated	Goldman	Buy	$45
Dec-01-22	Initiated	BofA Securities	Buy	$34

Show Previous Ratings

Feb-03-26 05:20PM	AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit (Motley Fool)
Feb-02-26 12:27PM	Will Declining Medical Customers Affect Cigna's Q4 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Jan-27-26 10:00AM	Best Momentum Stocks to Buy for January 27th (Zacks)
04:16AM	New Strong Buy Stocks for January 27th (Zacks)
07:32AM	Loading…
Jan-23-26 07:32AM	Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Jan-21-26 04:54AM	'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks (Benzinga)
Jan-15-26 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet (Zacks)
Jan-13-26 09:21AM	Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? (Zacks) -6.53%
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily) +26.73%
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
Jan-11-26 05:00PM	Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance (GlobeNewswire)
Jan-08-26 05:00AM	Day One concludes Mersana Therapeutics acquisition (Pharmaceutical Technology)
Jan-06-26 09:02AM	Day One Completes Acquisition of Mersana Therapeutics (GlobeNewswire)
Dec-16-25 08:30AM	Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
11:11PM	Loading…
Dec-15-25 11:11PM	Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) (Insider Monkey)
Dec-11-25 10:31AM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
Nov-24-25 08:00AM	Day One Announces Three Year Follow-Up Data From OJEMDA (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-18-25 08:30AM	Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-17-25 09:55AM	Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade (Zacks)
Nov-13-25 04:31PM	Mersana Therapeutics Catapults 200% On Day One Bio's Surprise Buyout (Investor's Business Daily) -14.41%
09:07AM	Mersana Catapults 200% On Day One Bio's Surprise Buyout (Investor's Business Daily)
06:59AM	Day One snaps up ADC maker Mersana in backloaded buyout deal (BioPharma Dive)
06:00AM	Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases (GlobeNewswire)
Nov-10-25 07:00AM	Day One Announces New OJEMDA (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-05-25 12:06AM	Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +25.21%
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Day One Reports Third Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
Nov-03-25 07:53AM	Day One Biopharmaceuticals Inc (DAWN) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 09:55AM	Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
08:30AM	Loading…
Oct-21-25 08:30AM	Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025 (GlobeNewswire)
Oct-14-25 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet (Zacks)
Oct-06-25 09:40AM	Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? (Zacks) -8.18%
Sep-16-25 08:01AM	Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-08-25 12:30AM	Piper Sandler Starts Coverage on Day One (DAWN) with Overweight Rating (Insider Monkey)
Aug-19-25 12:10AM	H.C. Wainwright Reiterates 'Buy' Rating on Day One Biopharmaceuticals, Inc. (DAWN) (Insider Monkey)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-06-25 03:31AM	Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) -15.70%
Aug-05-25 04:00PM	Day One Reports Second Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
Aug-04-25 09:54AM	Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q2 2025 Result (GuruFocus.com)
Jul-24-25 09:55AM	Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade (Zacks)
Jul-22-25 08:30AM	Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 (GlobeNewswire)
Jun-10-25 08:30AM	Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development (GlobeNewswire)
May-13-25 10:47AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey)
May-09-25 07:54AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 11:09AM	Q1 2025 Day One Biopharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.87%
03:21AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 05:25PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.55%
04:01PM	Day One Reports First Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
May-05-25 10:00AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com) -5.67%
May-03-25 02:13AM	Q1 2025 American International Group Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-23-25 02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-22-25 08:30AM	Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 (GlobeNewswire)
Apr-10-25 11:51PM	Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity (Seeking Alpha) -7.02% +5.33%
Apr-09-25 09:44AM	Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple (Insider Monkey) +8.35%
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-20-25 01:00AM	EXCLUSIVE: Plant Medicine Brand Apothékary Is Taking Customers on a $10,000 Immersive Trip to Japan (WWD)
Mar-05-25 09:00AM	Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory (Insider Monkey) +12.79%
Feb-25-25 05:55PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -16.50%
04:05PM	Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress (GlobeNewswire)
01:36AM	Day One Biopharmaceuticals Inc (DAWN) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-13-25 09:55AM	Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? (Zacks)
Feb-11-25 08:30AM	Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 (GlobeNewswire)
Jan-28-25 08:56AM	Trump pledged to bring down food prices on Day One. Instead, eggs are getting more expensive (CNN Business)
05:30AM	Trump said hed bring prices down on Day One. That hasnt happened (CNN Business)
Jan-23-25 01:02AM	Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? (Insider Monkey)
Jan-22-25 08:44AM	New Tariffs Didnt Come on Trumps Day One. A Trade War May Not Be in the Wings. (Barrons.com)
Jan-20-25 03:31PM	President Trump outlines a frenzy of Day One executive orders and actions: Heres a list of what to expect (FastCompany)
Jan-13-25 08:00AM	Day One Reports Preliminary 2024 OJEMDA Net Product Revenue and Highlights 2025 Corporate Priorities (GlobeNewswire)
Dec-24-24 04:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-22-24 03:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-19-24 03:19PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-17-24 08:30AM	Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 09:49AM	How Trump Can Help Crypto on Day One (CoinDesk)
Dec-06-24 08:53PM	Instagram locks out developers of third-party consumer apps (TechCrunch)
Nov-27-24 10:18AM	Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)
Nov-20-24 04:30PM	Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development (GlobeNewswire)
Nov-18-24 08:30AM	Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Oct-30-24 05:20PM	Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Day One Reports Third Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
Oct-21-24 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet (Zacks)
Oct-16-24 08:44AM	Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma (Insider Monkey)
08:30AM	Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 (GlobeNewswire)
Oct-01-24 08:00PM	At What Oil Price Will Shale Drillers Stop Drilling? (Oilprice.com)
Aug-27-24 12:49PM	Taylor Fritzs Girlfriend Morgan Riddle Opts for Classic Little Black Dress on Day One of the U.S. Open 2024 (WWD)
Aug-19-24 11:15AM	Jeff Bezos Said 'I Predict One Day Amazon Will Fail' And Claims Large Companies Only Last '30-Plus Years' Guess How Old Amazon Is? (Benzinga)
Aug-14-24 11:46AM	Bank of America Says Buy These 3 Stocks for a Double-Digit Rally (InvestorPlace)
Jul-30-24 01:52PM	DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:40AM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Day One Reports Second Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
07:00AM	Day One Announces Oversubscribed $175.0 Million Private Placement (GlobeNewswire)
Jul-25-24 11:53AM	Ipsen outlines $461m for ex-US rights to Day Ones glioma therapy (Pharmaceutical Technology)
12:58AM	Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor (GlobeNewswire)
Jun-27-24 09:51AM	Lupita Nyongo Shimmers in Sequined Off-the-shoulder Prada Jumpsuit and Satin Miniskirt at A Quiet Place: Day One Premiere (WWD)
Jun-24-24 04:50PM	Lupita Nyongo Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for A Quiet Place: Day One Photo Call (WWD)
Jun-22-24 04:11AM	Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
Jun-19-24 12:14PM	Day One targets the growing ADC market with MabCare acquisition (Pharmaceutical Technology)
10:29AM	Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up (Zacks)
Jun-18-24 08:30AM	Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers (GlobeNewswire) +11.31%

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dubow Adam	Gen Counsel & Secretary	Nov 17 '25	Sale	8.91	4,319	38,503	62,626	Nov 18 07:04 PM
York Charles N II	COO and CFO	Nov 17 '25	Sale	8.91	4,062	36,212	294,715	Nov 18 07:02 PM
Merendino Lauren	Chief Commercial Officer	Nov 17 '25	Sale	8.91	3,726	33,216	50,809	Nov 18 07:00 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Nov 17 '25	Sale	8.91	15,894	141,690	177,165	Nov 18 06:59 PM
CHARLES YORK	Officer	Nov 17 '25	Proposed Sale	8.91	4,062	36,211		Nov 17 04:12 PM
LAUREN MERENDINO	Officer	Nov 17 '25	Proposed Sale	8.91	3,726	33,216		Nov 17 04:12 PM
ADAM DUBOW	Officer	Nov 17 '25	Proposed Sale	8.91	4,319	38,502		Nov 17 04:11 PM
JEREMY BENDER	Officer	Nov 17 '25	Proposed Sale	8.91	15,894	141,689		Nov 17 04:09 PM
York Charles N II	COO and CFO	Aug 18 '25	Sale	6.77	4,106	27,786	278,000	Aug 19 07:40 PM
Dubow Adam	Gen Counsel & Secretary	Aug 18 '25	Sale	6.77	4,365	29,538	54,858	Aug 19 07:38 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Aug 18 '25	Sale	6.77	16,058	108,666	161,365	Aug 19 07:37 PM
Merendino Lauren	Chief Commercial Officer	Aug 18 '25	Sale	6.77	3,766	25,485	41,931	Aug 19 07:36 PM
JEREMY BENDER	Officer	Aug 18 '25	Proposed Sale	6.77	16,058	108,666		Aug 18 05:33 PM
Merendino Lauren	Chief Commercial Officer	May 16 '25	Sale	6.26	3,927	24,575	35,161	May 19 05:54 PM
Dubow Adam	GENERAL COUNSEL	May 16 '25	Sale	6.26	4,552	28,486	47,136	May 19 05:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 16 '25	Sale	6.26	4,282	26,796	265,231	May 19 05:45 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 16 '25	Sale	6.26	13,964	87,385	145,737	May 19 05:44 PM
CHARLES YORK	Officer	May 16 '25	Proposed Sale	6.26	4,282	26,796		May 16 04:09 PM
LAUREN MERENDINO	Officer	May 16 '25	Proposed Sale	6.26	3,927	24,575		May 16 04:09 PM
ADAM DUBOW	Officer	May 16 '25	Proposed Sale	6.26	4,552	28,486		May 16 04:08 PM
JEREMY BENDER	Officer	May 16 '25	Proposed Sale	6.26	13,964	87,385		May 16 04:08 PM
York Charles N II	COO, CFO AND SECRETARY	Feb 18 '25	Sale	11.96	4,370	52,278	252,638	Feb 21 06:10 PM
Dubow Adam	GENERAL COUNSEL	Feb 18 '25	Sale	11.96	4,646	55,580	39,602	Feb 21 06:08 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	11.96	12,048	144,130	128,015	Feb 21 06:05 PM
ADAM DUBOW	Officer	Feb 18 '25	Proposed Sale	11.96	4,646	55,580		Feb 18 06:07 PM
CHARLES YORK	Officer	Feb 18 '25	Proposed Sale	11.96	4,370	52,278		Feb 18 06:04 PM
JEREMY BENDER	Officer	Feb 18 '25	Proposed Sale	11.96	12,048	144,129		Feb 18 06:02 PM

KRRO

Korro Bio Inc

DYN

Dyne Therapeutics Inc

DAWN

Day One Biopharmaceuticals Inc

Upgrade your FINVIZ experience